Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
March 09, 2021 07:00 ET | Evelo Biosciences, Inc.
–Announced new positive data in human experimental model of inflammation of EDP1815––Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now...
evelo-logo.png
Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021
March 02, 2021 07:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
evelo-logo.png
Evelo Biosciences Appoints John A. Hohneker, M.D. to Board of Directors
February 16, 2021 07:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
evelo-logo.png
Evelo Biosciences Announces Pricing of Public Offering of Common Stock
January 28, 2021 21:08 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines,...
evelo-logo.png
Evelo Biosciences Announces Proposed Public Offering of Common Stock
January 28, 2021 16:01 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines,...
evelo-logo.png
Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis
January 20, 2021 07:00 ET | Evelo Biosciences, Inc.
–EDP1815 was well tolerated, and showed clinically meaningful and consistent changes in all measured physician-reported outcomes – –Improvements in patient-reported outcomes in DLQI and POEM,...
evelo-logo.png
Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones
January 07, 2021 07:00 ET | Evelo Biosciences, Inc.
-- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- -- Accelerate delivery of interim clinical data from EDP1815 Phase 2 psoriasis trial...
evelo-logo.png
Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer
December 21, 2020 07:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates...
evelo-logo.png
Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer
December 09, 2020 09:00 ET | Evelo Biosciences, Inc.
–EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503––Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product...
evelo-logo.png
Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis
December 09, 2020 07:00 ET | Evelo Biosciences, Inc.
–Treatment with EDP1815 demonstrates statistically and clinically significant improvement in mean EASI and IGA* BSA scores––EDP1815 first-ever candidate targeting SINTAX™ to show clinical activity in...